Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer ; volume:15 ; number:1 ; day:1 ; month:8 ; year:2015 ; pages:1-12 ; date:12.2015
BMC cancer ; 15, Heft 1 (1.8.2015), 1-12, 12.2015
- Urheber
-
Hennig, Ewa E.
- Beteiligte Personen und Organisationen
-
Piątkowska, Magdalena
Karczmarski, Jakub
Goryca, Krzysztof
Brewczynska, Elzbieta
Jazwiec, Radoslaw
Kluska, Anna
Omiotek, Robert
Paziewska, Agnieszka
Dadlez, Michal
Ostrowski, Jerzy
SpringerLink (Online service)
- DOI
-
10.1186/s12885-015-1575-4
- URN
-
urn:nbn:de:1111-2016110620390
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hennig, Ewa E.
- Piątkowska, Magdalena
- Karczmarski, Jakub
- Goryca, Krzysztof
- Brewczynska, Elzbieta
- Jazwiec, Radoslaw
- Kluska, Anna
- Omiotek, Robert
- Paziewska, Agnieszka
- Dadlez, Michal
- Ostrowski, Jerzy
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data
Influence of CYP2D6 genotype on tamoxifen efficacy in advanced breast cancer
Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation For Commonly Used CYP2D6*3 Genotyping Assays
Overcoming CYP2D6-mediated tamoxifen resistance in postmenopausal breast cancer : a PBPK approach
Publisher Correction: Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
Multiplex SNaPshot—a new simple and efficient CYP2D6 and ADRB1 genotyping method
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application
Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status
Tamoxifen
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data
Influence of CYP2D6 genotype on tamoxifen efficacy in advanced breast cancer
Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation For Commonly Used CYP2D6*3 Genotyping Assays
Overcoming CYP2D6-mediated tamoxifen resistance in postmenopausal breast cancer : a PBPK approach
Publisher Correction: Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
Multiplex SNaPshot—a new simple and efficient CYP2D6 and ADRB1 genotyping method
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application
Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status
Tamoxifen
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data
Influence of CYP2D6 genotype on tamoxifen efficacy in advanced breast cancer
Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation For Commonly Used CYP2D6*3 Genotyping Assays
Overcoming CYP2D6-mediated tamoxifen resistance in postmenopausal breast cancer : a PBPK approach
Publisher Correction: Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
Multiplex SNaPshot—a new simple and efficient CYP2D6 and ADRB1 genotyping method
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application
Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status